AK Medical Holdings Limited reported that it repurchased 1.37 million ordinary shares on 22 June 2026 via on-market transactions at an average price of HKD 5.25 per share, for a total consideration of HKD 7.18 million. The purchase represented 0.12% of the company’s issued share capital (excluding treasury shares) as at 18 June 2026.

Following the transaction, the company’s outstanding share count (excluding treasury shares) fell to 1.11 billion, while treasury shares increased to 14.78 million, equivalent to 1.31% of total issued shares.

The buyback was executed under the general mandate approved on 17 June 2026, which allows for the repurchase of up to 112.46 million shares. To date, AK Medical has acquired 30.34 million shares, representing 2.70% of the shares in issue at the time the mandate was granted.

In addition, 15.56 million shares (approximately 1.40% of the latest issued share base) that were repurchased between February and early June 2026 remain outstanding pending formal cancellation. Repurchase prices for these earlier transactions ranged from HKD 5.67 to HKD 7.00 per share.

Under Hong Kong Stock Exchange requirements, AK Medical is subject to a moratorium on issuing new shares or selling treasury shares until 22 July 2026.